These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 5450048)

  • 1. [1-dopa for parkinsonism].
    Flatberg P
    Tidsskr Nor Laegeforen; 1970 May; 90(10):1102-3. PubMed ID: 5450048
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of parkinsonism with L-Dopa associated with decarboxylase inhibitors. II].
    Gauthier G; de Ajuriaguerra J; Simona B; Constantinidis J; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Rev Neurol (Paris); 1970 Nov; 123(5):297-319. PubMed ID: 5513630
    [No Abstract]   [Full Text] [Related]  

  • 3. [L-dopa and parkinsonism. A preliminary report].
    Pakkenberg H
    Ugeskr Laeger; 1969 May; 131(22):959-60. PubMed ID: 5793628
    [No Abstract]   [Full Text] [Related]  

  • 4. [Use of L-DOPA in the therapy of parkinsonism].
    D'Andrea F; De Divitiis E; Signorelli CD; Cerillo A; Tedeschi G
    Rass Int Clin Ter; 1971 Feb; 51(4):193-221. PubMed ID: 4930734
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical effect of L-DOPA and electromyographic study of Parkinsonism].
    Sato G; Ito H; Handa Y; Takahashi I; Iijima K
    No To Shinkei; 1971 Mar; 23(3):325-32. PubMed ID: 5107821
    [No Abstract]   [Full Text] [Related]  

  • 6. [L-DOPA therapy of parkinsonism].
    Refsum S
    Nord Med; 1969 May; 81(18):570-1. PubMed ID: 5768311
    [No Abstract]   [Full Text] [Related]  

  • 7. [Long term treatment of a parkinsonism with l-dopa].
    Presthus J
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2111-3. PubMed ID: 4590069
    [No Abstract]   [Full Text] [Related]  

  • 8. Metabolism and clinical assessment of L-dopa in parkinsonism.
    Ericsson AD; McCann D; Sharpless N; Reveno W
    Neurology; 1970 Apr; 20(4):402. PubMed ID: 4935027
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapeutic guidelines and side effects encountered during L-dopa therapy in 100 cases of parkinsonism.
    Jenkins AC; Schwieger AC
    Med J Aust; 1971 Oct; 2(14):693-700. PubMed ID: 5114186
    [No Abstract]   [Full Text] [Related]  

  • 10. L-dopa for Parkinsonism.
    Drug Ther Bull; 1969 Jul; 7(15):59-60. PubMed ID: 5806494
    [No Abstract]   [Full Text] [Related]  

  • 11. L-dopa and amantadine in the therapy of parkinsonism.
    Weeth JB; Shealy CN; Mercier DA
    Wis Med J; 1969 Nov; 68(11):325-8. PubMed ID: 4901055
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical experience with L-DOPA in the treatment of parkinsonism].
    Chiba T
    No To Shinkei; 1970 Dec; 22(12):1399-405. PubMed ID: 5536833
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of parkinsonism with L-dopa].
    Court J; Kase JC; Palacios E; Mena I
    Rev Med Chil; 1971 Jun; 99(6):399-401. PubMed ID: 5561157
    [No Abstract]   [Full Text] [Related]  

  • 14. Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486).
    Yahr MD; Duvoisin RC; Mendoza MR; Schear MJ; Barrett RE
    Trans Am Neurol Assoc; 1971; 96():55-8. PubMed ID: 5159129
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines].
    Uono M; Tanabe H; Yano Y; Nakao K
    No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082
    [No Abstract]   [Full Text] [Related]  

  • 16. [L-dopa and Parkinson's disease].
    Barbeau A
    Union Med Can; 1970 Dec; 99(12):2195-7. PubMed ID: 5488646
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
    Wajsbort J; Hemli JA; Alfandary I; Yahel M; Siegfried J
    Wien Med Wochenschr; 1971 Oct; 121(42):741-5. PubMed ID: 5115985
    [No Abstract]   [Full Text] [Related]  

  • 18. Experimental treatment of parkinsonism with L-Dopa.
    Cotzias GC; Papavasiliou PS; Gellene R
    Neurology; 1968 Mar; 18(3):276-7. PubMed ID: 4869717
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
    Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
    [No Abstract]   [Full Text] [Related]  

  • 20. [Our experience with the treatment of Parkinson's disease with L-dopa].
    Buscaino GA; Campanella G
    Acta Neurol (Napoli); 1971; 26(1):46-60. PubMed ID: 5553941
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.